Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets with no systematic search or new human data.
PubMed 23121386 · doi:10.1111/bph.12037
What was done
The authors reviewed the role of central peptidergic systems in regulating energy homeostasis, specifically evaluating the therapeutic potential of blocking orexigenic signals (such as neuropeptide Y, melanin-concentrating hormone, orexins, relaxin-3, and galanin-like peptide) or stimulating anorectic pathways (such as melanocortins, ciliary neurotrophic factor, and brain-derived neurotrophic factor) for obesity.
What was found
The abstract reports no numerical data. It notes that modulating these central neuropeptide systems shows potential for obesity treatment, but development faces significant challenges including brain delivery access, adverse side effects, and counter-regulatory homeostatic defense of body weight that may require combination therapies rather than single-target approaches.
Why it matters
This review outlines the therapeutic landscape of central peptidergic targets and highlights key biological barriers that inform anti-obesity drug design.
Limits
As a narrative review, it presents no original empirical data, no sample sizes, no quantitative outcome measures, and no systematic search protocol.
Cited by
- supports The orexin (hypocretin) system is involved in hunger regulation and has implications for the treatment of obesity.